41 institutions hold shares in Soligenix Inc. (SNGX), with 1.15M shares held by insiders accounting for 2.87% while institutional investors hold 9.50% of the company’s shares. The shares outstanding are 30.03M, and float is at 18.52M with Short Float at 9.83%. Institutions hold 9.23% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 0.91 million shares valued at $1.16 million. The investor’s holdings represent 2.27% of the SNGX Shares outstanding. As of Dec 30, 2020, the second largest holder is Knoll Capital Management, L.P. with 0.79 million shares valued at $1.01 million to account for 1.97% of the shares outstanding. The other top investors are First Wilshire Securities Management Inc which holds 0.35 million shares representing 0.87% and valued at over $0.45 million, while Geode Capital Management, LLC holds 0.32% of the shares totaling 0.13 million with a market value of $0.16 million.
Soligenix Inc. (NASDAQ: SNGX) is 23.44% higher on its value in year-to-date trading and has touched a low of $1.21 and a high of $2.99 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SNGX stock was last observed hovering at around $1.57 in the last trading session, with the day’s gains setting it 0.01% off its average median price target of $2.00 for the next 12 months. It is also 21.0% off the consensus price target high of $2.00 offered by 1 analysts, but current levels are 21.0% higher than the price target low of $2.00 for the same period.
Currently trading at $1.58, the stock is -4.18% and -7.53% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.91 million and changing 0.64% at the moment leaves the stock -15.89% off its SMA200. SNGX registered 6.76% gain for a year compared to 6-month loss of -9.20%. The firm has a 50-day simple moving average (SMA 50) of $1.7118 and a 200-day simple moving average (SMA200) of $1.7891.
The stock witnessed a 3.27% gain in the last 1 month and extending the period to 3 months gives it a 17.04%, and is 6.04% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.36% over the week and 7.57% over the month.
Soligenix Inc. (SNGX) has around 15 employees, a market worth around $46.28M and $2.70M in sales. Distance from 52-week low is 30.58% and -47.16% from its 52-week high.
Soligenix Inc. (SNGX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Soligenix Inc. (SNGX) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 2.50, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Soligenix Inc. is expected to release its quarterly report on 08/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.11 with sales reaching $600k over the same period.The EPS is expected to grow by 46.90% this year, but quarterly earnings will post 23.30% year-over-year. Quarterly sales are estimated to shrink -35.10% in year-over-year returns.
Soligenix Inc. (SNGX) Insider Activity
A total of 0 insider transactions have happened at Soligenix Inc. (SNGX) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Soligenix Inc. (SNGX): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 21.78% up over the past 12 months and Cleveland BioLabs Inc. (CBLI) that is 247.02% higher over the same period. Sanofi (SNY) is 11.06% up on the 1-year trading charts. Short interest in the company’s stock has risen 15.38% from the last report on Feb 11, 2021 to stand at a total of 1.54 million short shares sold with a short interest ratio of 0.44.